Literature DB >> 3277996

Human coproantibody secretory immunoglobulin A response to Yersinia species.

K M Fletcher1, C M Morris, M A Noble.   

Abstract

A semiquantitative indirect immunofluorescence assay to detect coproantibody secretory IgA (SIgA) was established to investigate the human intestinal immune response to Yersinia species. This assay was based on microagglutination of SIgA in fecal specimens with the patient's homologous organism. Two populations of patients were defined, those who produced an agglutinating (2+) SIgA response and those who did not. A comparison between SIgA production and standard in vitro virulence-related characteristics of infecting organisms, including autoagglutination, calcium dependence, plasmid carriage, and absorption of Congo red, mouse virulence, and clinical presentation, was performed. A positive (2+) SIgA result was associated with acute enteric illness (positive predictive value, 78.6%) and mouse virulence (positive predictive value, 85.7%). When patients with active inflammatory bowel disease were excluded, the positive predictive value of SIgA for mouse virulence and acute enteric disease became 100%. In addition to strains of Yersinia enterocolitica 4,O:3, strains generally characterized as nonpathogenic, including Yersinia frederiksenii, were found to be associated with acute disease, mouse virulence, and stimulation of SIgA. The indirect immunofluorescence assay for detection of SIgA response appears to be a useful indicator of pathogenic strains of yersiniae recovered from enteric specimens.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3277996      PMCID: PMC266269          DOI: 10.1128/jcm.26.2.287-292.1988

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  25 in total

1.  Coproantibody Excretion During Enteric Infections.

Authors:  P E Harrison; J Banvard
Journal:  Science       Date:  1947-08-29       Impact factor: 47.728

2.  Yersiniosis as an internal disease.

Authors:  R Leino; J L Kalliomäki
Journal:  Ann Intern Med       Date:  1974-10       Impact factor: 25.391

3.  Antibacterial antibodies in rectal and colonic mucosa in ulcerative colitis.

Authors:  E Monteiro; J Fossey; M Shiner; B S Drasar; A C Allison
Journal:  Lancet       Date:  1971-02-06       Impact factor: 79.321

4.  Intestinal immunoglobulins in shigellosis.

Authors:  W P Reed; R C Williams
Journal:  Gastroenterology       Date:  1971-07       Impact factor: 22.682

5.  Correlation of autoagglutination and virulence of yersiniae.

Authors:  W J Laird; D C Cavanaugh
Journal:  J Clin Microbiol       Date:  1980-04       Impact factor: 5.948

6.  Gastrointestinal features of culture-positive Yersinia enterocolitica infection.

Authors:  S D Simmonds; M A Noble; H J Freeman
Journal:  Gastroenterology       Date:  1987-01       Impact factor: 22.682

7.  Yersiniosis as a gastrointestinal disease.

Authors:  R Leino; K Granfors; T Havia; R Heinonen; M Lampinen; A Toivanen
Journal:  Scand J Infect Dis       Date:  1987

8.  Heat-stable enterotoxin produced by Yersinia enterocolitica isolated from patients.

Authors:  K Okamoto; H Ichikawa; Y Kawamoto; A Miyama; S Yoshii
Journal:  Microbiol Immunol       Date:  1980       Impact factor: 1.955

9.  Yersinia enterocolitica: guidelines for serologic diagnosis of human infections.

Authors:  E J Bottone; D J Sheehan
Journal:  Rev Infect Dis       Date:  1983 Sep-Oct

10.  Yersinia enterocolitica infection in resistant and susceptible strains of mice.

Authors:  G E Hancock; R W Schaedler; T T MacDonald
Journal:  Infect Immun       Date:  1986-07       Impact factor: 3.441

View more
  2 in total

1.  Routine culturing of stool specimens for Yersinia enterocolitica.

Authors:  R L Barteluk; M A Noble
Journal:  J Clin Microbiol       Date:  1988-08       Impact factor: 5.948

2.  Pathogenicity of Yersinia kristensenii for mice.

Authors:  R M Robins-Browne; S Cianciosi; A M Bordun; G Wauters
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.